Polymyxin B versus colistin: an update

被引:97
作者
Cai, Yiying [1 ,3 ]
Lee, Winnie [1 ]
Kwa, Andrea L. [1 ,2 ,3 ]
机构
[1] Singapore Gen Hosp, Dept Pharm, Singapore 169608, Singapore
[2] Duke NUS Grad Med Sch, Emerging Infect Dis, Singapore 169857, Singapore
[3] Natl Univ Singapore, Dept Pharm, Singapore 119077, Singapore
关键词
colistimethate sodium; colistin sulfate; multi-drug resistance; pharmacokinetics and pharmacodynamics; polymyxin B; polymyxin combination therapy; polymyxins; polypeptide antibiotics; CRITICALLY-ILL PATIENTS; RESISTANT ACINETOBACTER-BAUMANNII; IN-VITRO PHARMACODYNAMICS; SODIUM SULPHOMETHYL DERIVATIVES; GRAM-NEGATIVE BACTERIA; MULTIDRUG-RESISTANT; PSEUDOMONAS-AERUGINOSA; COMBINATION THERAPY; POPULATION PHARMACOKINETICS; INDUCED NEPHROTOXICITY;
D O I
10.1586/14787210.2015.1093933
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Polymyxin B and colistin (polymyxin E) are polypeptide antibiotics that were developed in the 1940s, but fell into disfavor due to their high toxicity rates. These two antibiotics were previously regarded to be largely equivalent, due to similarities in their chemical structure and spectrum of activity. In recent years, several pertinent differences, especially in terms of potency and disposition, have been revealed between polymyxin B and colistin. These differences are mainly attributed to the fact that polymyxin B is administered parenterally in its active form, while colistin is administered parenterally as an inactive pro-drug, colistimethate. In this review, we summarize the similarities and differences between polymyxin B and colistin. We also discuss the potential clinical implications of these findings, and provide our perspectives on how polymyxins should be employed to preserve their utility in this era of multi-drug resistance.
引用
收藏
页码:1481 / 1497
页数:17
相关论文
共 121 条
  • [1] Characterization of Polymyxin B-Induced Nephrotoxicity: Implications for Dosing Regimen Design
    Abdelraouf, Kamilia
    Braggs, Kirk H.
    Yin, Taijun
    Truong, Luan D.
    Hu, Ming
    Tam, Vincent H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) : 4625 - 4629
  • [2] Higher Incidence of Acute Kidney Injury With Intravenous Colistimethate Sodium Compared With Polymyxin B in Critically Ill Patients at a Tertiary Care Medical Center
    Akajagbor, Darowan S.
    Wilson, Sharon L.
    Shere-Wolfe, Kapana D.
    Dakum, Paul
    Charurat, Manhattan E.
    Gilliam, Bruce L.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 (09) : 1300 - 1303
  • [3] Colistin Pharmacokinetics in Burn Patients during Continuous Venovenous Hemofiltration
    Akers, Kevin S.
    Rowan, Matthew P.
    Niece, Krista L.
    Stewart, Ian J.
    Mende, Katrin
    Cota, Jason M.
    Murray, Clinton K.
    Chung, Kevin K.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 46 - 52
  • [4] Polymyxin B Hemoperfusion in Sepsis: Growing Body of Evidence and Occasional Conflicting Results
    Antonelli, Massimo
    Ronco, Claudio
    [J]. BLOOD PURIFICATION, 2015, 39 (1-3) : I - II
  • [5] SODIUM SULPHOMETHYL DERIVATIVES OF POLYMYXINS
    BARNETT, M
    BUSHBY, SRM
    WILKINSON, S
    [J]. BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1964, 23 (03): : 552 - +
  • [6] In Vitro Activity of Polymyxin B plus Imipenem, Meropenem, or Tigecycline against KPC-2-Producing Enterobacteriaceae with High MICs for These Antimicrobials
    Barth, Natalia
    Ribeiro, Vanessa B.
    Zavascki, Alexandre P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3596 - 3597
  • [7] Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
    Batirel, A.
    Balkan, I. I.
    Karabay, O.
    Agalar, C.
    Akalin, S.
    Alici, O.
    Alp, E.
    Altay, F. A.
    Altin, N.
    Arslan, F.
    Aslan, T.
    Bekiroglu, N.
    Cesur, S.
    Celik, A. D.
    Dogan, M.
    Durdu, B.
    Duygu, F.
    Engin, A.
    Engin, D. O.
    Gonen, I.
    Guclu, E.
    Guven, T.
    Hatipoglu, C. A.
    Hosoglu, S.
    Karahocagil, M. K.
    Kilic, A. U.
    Ormen, B.
    Ozdemir, D.
    Ozer, S.
    Oztoprak, N.
    Sezak, N.
    Turhan, V.
    Turker, N.
    Yilmaz, H.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2014, 33 (08) : 1311 - 1322
  • [8] Antifungal Activity of Colistin against Mucorales Species In Vitro and in a Murine Model of Rhizopus oryzae Pulmonary Infection
    Ben-Ami, Ronen
    Lewis, Russell E.
    Tarrand, Jeffrey
    Leventakos, Konstantinos
    Kontoyiannis, Dimitrios P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 484 - 490
  • [9] Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa
    Bergen, Phillip J.
    Li, Jian
    Rayner, Craig R.
    Nation, Roger L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 1953 - 1958
  • [10] Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model
    Bergen, Phillip J.
    Bulitta, Jurgen B.
    Forrest, Alan
    Tsuji, Brian T.
    Li, Jian
    Nation, Roger L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) : 3783 - 3789